TR199802482T2 - 10-aminoaliphatyl-dibenz[b,f]oxepin salts with anti-neurodegenerative action. - Google Patents

10-aminoaliphatyl-dibenz[b,f]oxepin salts with anti-neurodegenerative action.

Info

Publication number
TR199802482T2
TR199802482T2 TR1998/02482T TR9802482T TR199802482T2 TR 199802482 T2 TR199802482 T2 TR 199802482T2 TR 1998/02482 T TR1998/02482 T TR 1998/02482T TR 9802482 T TR9802482 T TR 9802482T TR 199802482 T2 TR199802482 T2 TR 199802482T2
Authority
TR
Turkey
Prior art keywords
aliphatic
aminoaliphatyl
dibenz
salts
oxepin
Prior art date
Application number
TR1998/02482T
Other languages
Turkish (tr)
Inventor
Zimmermann Kaspar
Roggo Silvio
Betschart Claudia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR199802482T2 publication Critical patent/TR199802482T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formül 1'in 10-aminoalifatil-dibenz [b,f] oksepinlerinin asit katki tuzlari Ki içinde alk bir çiftdegerleri, alifatik kökü gösterir, R tek degerli alifatik ve/veya aralifatik köklerin tek-veya çift-yerine kullanilmis veya kullanilmamis, veya alifatik veya aralifatik köklerin çift yerine kullanilmis bir amino grubu temsil eder ve R1, R2, R3, ve R4, bir digerinden bagimsiz olarak, hidrojeni, düsük alkili, düsük alkoksiyi, halojeni veya triflorometili organik karboksilik asitlerle, ilaçlar için karisimdaki anti-nörodejeneratif aktif maddeler olarak kullanilabilir. Bulus serbest formdaki formül 1 yeni bilesimleriyle de ilgilidir.Acid addition salts of the 10-aminoaliphatyl-dibenz [b, f] oxepins of formula 1 in Ki denote a couple of alky values, aliphatic root, R being single-or double-substituted or unused, or aliphatic or aliphatic aliphatic and / or araliphatic roots. represents an amino group that is used as a double substitute of araliphatic roots, and R1, R2, R3, and R4 can be independently used as an anti-neurodegenerative active ingredient for drugs with hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl organic carboxylic acids. . The invention also relates to new compounds of formula 1 in free form.

TR1998/02482T 1996-05-30 1997-05-28 10-aminoaliphatyl-dibenz[b,f]oxepin salts with anti-neurodegenerative action. TR199802482T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH135296 1996-05-30

Publications (1)

Publication Number Publication Date
TR199802482T2 true TR199802482T2 (en) 1999-02-22

Family

ID=4208469

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02482T TR199802482T2 (en) 1996-05-30 1997-05-28 10-aminoaliphatyl-dibenz[b,f]oxepin salts with anti-neurodegenerative action.

Country Status (10)

Country Link
AR (1) AR008371A1 (en)
AU (1) AU3030397A (en)
CO (1) CO5080765A1 (en)
CZ (1) CZ296134B6 (en)
ID (1) ID18178A (en)
PE (1) PE70398A1 (en)
PL (1) PL191728B1 (en)
TR (1) TR199802482T2 (en)
WO (1) WO1997045422A1 (en)
ZA (1) ZA974802B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016812A (en) * 1999-06-03 2002-03-06 구니이 야스오 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2003057204A2 (en) * 2002-01-08 2003-07-17 Nordic Bioscience A/S Modulation of iamt (pimt or pcmt) in immune system
EP1589963A1 (en) * 2003-01-29 2005-11-02 Novartis AG Use of 10-aminoaliphatyl-dibenz b,f oxepines for the tr eatment of degenerative ocular disorders
PE20050487A1 (en) * 2003-11-06 2005-10-07 Novartis Ag STABILIZED PHARMACEUTICAL COMPOSITIONS
EP1804804B1 (en) 2004-09-21 2012-01-25 Hypnion, Inc. 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
EP1757284A1 (en) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
DE1493782B1 (en) * 1964-06-29 1969-12-11 Geigy Ag J R Basically substituted dibenzo [b, f] -oxepines and their non-toxic salts
CH585745A5 (en) * 1973-06-08 1977-03-15 Hoffmann La Roche
DE59607332D1 (en) * 1995-02-08 2001-08-30 Novartis Ag Antineurodegenerative 10-aminoaliphatyl-dibenz-b, f oxepine

Also Published As

Publication number Publication date
ID18178A (en) 1998-03-12
ZA974802B (en) 1998-11-30
AU3030397A (en) 1998-01-05
PL191728B1 (en) 2006-06-30
CZ296134B6 (en) 2006-01-11
CO5080765A1 (en) 2001-09-25
AR008371A1 (en) 2000-01-19
PL330238A1 (en) 1999-05-10
CZ387898A3 (en) 1999-02-17
WO1997045422A1 (en) 1997-12-04
PE70398A1 (en) 1998-11-09

Similar Documents

Publication Publication Date Title
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
TR200002090T2 (en) 4- (2-keto-1-benzimidazolinyl) piperidine compounds that are Orl1-receptor agonists
EA200001154A1 (en) SOLID COMPOSITIONS CONTAINING DERIVATIVES OF GAMMA-AMINO-OIL ACID, AND METHOD OF THEIR OBTAINING
TR200400238T4 (en) Alpha crystalline form of the perindopril tert-butylamine salt
DE69722027D1 (en) CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
HUP9902409A2 (en) Inhibitors of cysteine protease
TR199700419A2 (en) New pyridazinone derivatives.
DE60329211D1 (en) CYTARABIN MONOPHOSPHATE PRODRUGS
NZ190816A (en) 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphanes and pharmaceutical compositions
EP0725074A3 (en) Compounds for use, therefore, intermediates for the preparation of androst-3,5-diene-3-carboxy derivatives
TR200002237T2 (en) Benzothiadiazole and its derivatives
TR200100909T2 (en) New crystal modification of Torasemid.
HUP0001603A2 (en) Cycloalkylalkanecarboxamides and the production and use thereof
EA200300044A1 (en) NEW SUBSTITUTED PHTHALIDES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
TR200200070T2 (en) Titanium-derived compounds, their preparation and use.
TR199800624T1 (en) Yeni 5-0- deosaminil 6-0-metil erythronolid a t�revleri, buynar�n kullan�m�.
MY113427A (en) Anti-neurodegeneratively active 10-aminoaliphatyl- dibenz [b,f] oxepines
SE7513391L (en) METHOD OF PREPARING SALTS OF PIPERIDYL CONTENT DERIVATIVES
WO2002036553A3 (en) Substituted alkanoic acids
TR200001909T2 (en) Matrix metalloprosthesis inhibitors.
MXPA05013499A (en) COMPOSITIONS OF ORAL RINSE CONTAINING SALTS OF N-ACIL-ARGININA RENTAL ESTER.
JPS5793977A (en) Acylaminoquinazoline derivative and its preparation
DE60025171D1 (en) 1-ACYL-7-NITROINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHOTOSPATIBLE PRE-STAGES
TR199800410T1 (en) New carboxylic acid derivatives, their preparation and use.
TR200001052T2 (en) Plant growth regulatory composition.